GeneDx Holdings Corp (WGS) reports a 27% increase in quarterly revenue, driven by robust exome and genome sales, while setting ambitious targets for 2026.

Q4 2025 Management View Katherine Stueland, President and CEO, indicated that "the fourth quarter was a strong finish to a transformative year for GeneDx," reporting quarterly revenues of $121 million ...

We reported quarterly revenues of $121,000,000, bringing full-year revenues to $428,000,000, underpinned by 54% exome and ...

Congenital diaphragmatic hernia (CDH) is a common, life-threatening birth defect. Often, CDH occurs with other birth defects (CDH+). In a new study, researchers at Baylor College of Medicine have ...

A new Points to Consider document from the ACMG aims to assist referring physicians, laboratory geneticists, genetic counselors and other medical professionals in understanding the complexity and ...

In the two decades since the Human Genome Project mapped the entire human genome, improvements in technology have helped in developing updated reference genomes used for sequencing. But while the ...

Researchers at New York University, Weill Cornell Medicine and New York Genome Center have developed and tested a two-step approach that uses whole-exome sequencing to find genes and pathways that ...

Immunotherapies, such as immune checkpoint inhibitors, have transformed the treatment of advanced stage cancers. Unlike chemotherapies that kill cancer cells, these drugs help the body's immune system ...

Scientists at the Boston University School of Medicine with other researchers on the Alzheimer’s Disease Sequencing Project (ADSP) have discovered new genes that could further current understanding of ...